MW 317.4 Da, Purity >99%. ATP-competitive PKD inhibitor. Antiproliferative agent. Inhibits tumor cell invasion and induces G2/M arrest. ATP and PP1 analog.
Images
Key facts
- CAS number
- 221243-82-9
- Purity
- > 99%
- Form
- Solid
- Molecular weight
- 317.4 Da
- Molecular formula
- C19H19N5
- PubChem identifier
- 4877
- Nature
- Synthetic
Target data
Alternative names
ABL, ABL proto oncogene 1 non receptor tyrosine kinase, ABL1_HUMAN, AI849689, Abelson murine leukemia viral oncogene homolog 1, Abelson tyrosine protein kinase 1, Alpha CaMKII, Bcr/c abl oncogene protein, C SRC, C syn protooncogene, C-JUN kinase 1, C-SRC kinase, CAMK II, CAMKA, CARD 3, CARD carrying kinase, CARD containing ICE associated kinase, CARD containing interleukin 1 beta converting enzyme (ICE) associated kinase, CARD-containing IL-1 beta ICE-kinase, CARD-containing interleukin-1 beta-converting enzyme-associated kinase, CARDIAK, CKI-delta, CKId, CLARP kinase, CSK_HUMAN, CSNK 1D, CYTOPLASMIC TYROSINE KINASE, CaM kinase II alpha chain, CaM kinase II alpha subunit, CaM kinase II subunit alpha, CaMK II alpha subunit, CaMK-II subunit alpha, CaMKIINalpha, Calcium calmodulin dependent protein kinase II, Calcium/calmodulin dependent protein kinase II alpha B subunit, Calcium/calmodulin dependent protein kinase type II alpha chain, Calcium/calmodulin-dependent protein kinase (CaM kinase) II alpha, Calcium/calmodulin-dependent protein kinase II-alpha, Calcium/calmodulin-dependent protein kinase type II subunit alpha, Calcium/calmodulin-dependent protein kinase type IIA, Camk2a, Casein Kinase 1 delta, Casein kinase I delta isoform, Casein kinase I isoform delta, Cdc 2, Cell division control protein 2 homolog, Cell division protein kinase 2, Cell division protein kinase 4, Cell division protein kinase 5, Cell division protein kinase 9, Csk A, Cyclin-dependent kinase 1, Cyclin-dependent kinase 4, Cyclin-dependent kinase 5, Cyclin-dependent kinase 9, EC 2.7.10.2, EC 2.7.11.17, EC 2.7.11.24, FYN oncogene related to SRC FGR YES, FYN_HUMAN, GIG 30, Growth inhibiting gene 30, HCKID, IMD22, JNK, JNK 1, JNK-46, JNK1A2, JNK21B1/2, JTK7, KC1D_HUMAN, KCC2A_HUMAN, KIAA0968, KPCA_HUMAN, KPCD1_HUMAN, LCK proto-oncogene, Src family tyrosine kinase, LCK_HUMAN, LSK, Lck p56, Leukocyte C-terminal Src kinase, Lymphocyte cell-specific protein-tyrosine kinase, Lymphocyte specific protein tyrosine kinase, MAP kinase 8, MAPK 8, MGC112926, MGC117393, MGC123320, MGC139375, MGC154049, MGC155201, MK08_HUMAN, Membrane associated protein tyrosine kinase, Mitogen-activated protein kinase 8, OKT3 induced calcium influx regulator, Oncogene lck, P150, PK2CDD, PKC, PKC 2, PKC MU, PKC ZETA, PKC d, PKC delta, PKC epsilon, PKC-A, PKC-B, PKC-alpha, PKC-beta, PKC-gamma, PKCCD, PKCE, PKCG, PKCM, PKD, PRKC D, PRKCA, PRKCB, PRKCB1, PRKCB2, PRKCE, PRKCG, PRKCM, PRKCZ, PRKD 1, PRKM 8, Protein Kinase C alpha, Protein Kinase C delta, Protein YT16, Protein kinase C, Protein kinase C alpha type, Protein kinase C beta, Protein kinase C epsilon, Protein kinase C gamma, Protein kinase C mu, Protein kinase C mu type, Protein kinase C zeta, Protein kinase CK1 delta, Protein kinase D, Protein kinase D1, Protein kinase JNK1, Protein kinase, mitogen-activated, 8, Protein tyrosine kinase fyn, Protein-tyrosine kinase CYL, Proto oncogene tyrosine protein kinase, Proto oncogene tyrosine protein kinase ABL1, Proto oncogene tyrosine protein kinase LCK, Proto oncogene tyrosine protein kinase fyn, Proto-oncogene Lck, Proto-oncogene Syn, Proto-oncogene c-Abl, Proto-oncogene c-Fyn, R74975, RICK, RIP-like-interacting CLARP kinase, RIPK2_HUMAN, Receptor interacting protein (RIP) like interacting caspase like apoptosis regulatory protein (CLARP) kinase, Receptor interacting serine threonine kinase 2, Receptor-interacting protein 2, Receptor-interacting serine/threonine-protein kinase 2, SAPK 1, SAPK gamma, SYN, Serine/threonine-protein kinase D1, Src yes related novel gene, Src-like kinase, Src/yes related novel, Stress-activated protein kinase 1, Stress-activated protein kinase JNK1, T cell-specific protein-tyrosine kinase, T lymphocyte specific protein tyrosine kinase p56lck, TNFRSF, Tyrosine kinase p59fyn T, Tyrosine kinase p59fyn(T), Tyrosine-protein kinase ABL1, Tyrosine-protein kinase CSK, Tyrosine-protein kinase Fyn, Tyrosine-protein kinase Lck, Tyrosine-protein kinase RIPK2, UNQ277/PRO314/PRO34092, YT 16, bcr/abl, c ABL, c abl oncogene 1 non receptor tyrosine kinase, c abl oncogene 1 receptor tyrosine kinase, c-Jun N-terminal kinase 1, c-src tyrosine kinase, mKIAA0968, nPKC-D1, nPKC-mu, p33 protein kinase, p34 protein kinase, p54 gamma, p56(LSTRA) protein tyrosine kinase, p56-LCK, p59-Fyn, p60-Src, pp58 lck, v abl, v abl Abelson murine leukemia viral oncogene homolog 1, zgc:112538, zgc:123320, zgc:154049
Recommended products
MW 317.4 Da, Purity >99%. ATP-competitive PKD inhibitor. Antiproliferative agent. Inhibits tumor cell invasion and induces G2/M arrest. ATP and PP1 analog.
Key facts
- CAS number
- 221243-82-9
- Purity
- > 99%
- Form
- Solid
- Molecular weight
- 317.4 Da
- Molecular formula
- C19H19N5
- PubChem identifier
- 4877
- Nature
- Synthetic
- Solubility
Soluble in DMSO to 25 mM.
- Biochemical name
- 1-(tert-Butyl)-3-(naphthalen-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- Biological description
ATP-competitive PKD inhibitor. Antiproliferative agent. Inhibits tumor cell invasion and induces G2/M arrest. ATP and PP1 analog.
- Canonical SMILES
- CC(C)(C)N1C2=NC=NC(=C2C(=N1)C3=CC=CC4=CC=CC=C43)N
- InChI
- InChI=1S/C19H19N5/c1-19(2,3)24-18-15(17(20)21-11-22-18)16(23-24)14-10-6-8-12-7-4-5-9-13(12)14/h4-11H,1-3H3,(H2,20,21,22)
- InChIKey
- XSHQBIXMLULFEV-UHFFFAOYSA-N
- IUPAC name
- 1-tert-butyl-3-naphthalen-1-ylpyrazolo[3,4-d]pyrimidin-4-amine
Storage
- Shipped at conditions
- Ambient - Can Ship with Ice
- Appropriate short-term storage conditions
- -20°C
- Appropriate long-term storage conditions
- -20°C
- Storage information
- Store under desiccating conditions, The product can be stored for up to 12 months
Supplementary info
- This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
The target list comprises several kinases and regulatory proteins including PKC (Protein Kinase C) Cdks (Cyclin-dependent kinases) JNK1 (c-Jun N-terminal kinase 1) RIP2 (Receptor-interacting protein 2) CSK (C-terminal Src kinase) PKC mu/PKD (Protein kinase D) Fyn Lck (Lymphocyte-specific protein tyrosine kinase) CaMKII alpha (Calcium/calmodulin-dependent protein kinase II alpha) ABL1 and Casein Kinase 1 delta/CSNK1D. These proteins perform a variety of functions inside cells. For example PKC with a mass varying between 77 to 99 kDa depending on the isoform is expressed in various tissues and plays roles in signal transduction. Cdks act mostly in regulating the cell cycle. The proteins are located ubiquitously in cellular membranes cytosol and the nucleus depending on their roles and activation states.
- Biological function summary
The proteins listed above participate in essential cellular processes including signal transduction cell cycle control apoptosis and response to stress. For instance PKC is an important player in pathways controlling cellular responses to signals. Cdks bind to regulatory proteins called cyclins to regulate cell cycle transitions. These proteins often exist as parts of larger complexes to exert their functions. Many kinases such as JNK1 and RIP2 modulate immune and inflammatory responses while CSK negatively regulates Src family kinases by phosphorylation.
- Pathways
These proteins integrate into various essential biological pathways. PKC and CDKs play pivotal roles in the cell cycle and signaling pathways impacting cell growth and apoptosis. JNK1 is involved in the MAPK (Mitogen-activated protein kinase) pathway interacting with stress-related stimuli. In this network Fyn and Lck are non-receptor tyrosine kinases that participate in T-cell receptor signaling. CaMKII alpha ABL1 and Casein Kinase 1 delta also integrate into pathways related to cellular architecture and neurochemical responses.
- Associated diseases and disorders
PKC Cdks and JNK1 are implicated in cancer and neurodegenerative disorders such as Alzheimer's disease. Aberrant PKC expression and Cdks deregulation contribute to tumor development and progression. Similarly ABL1 when activated in BCR-ABL fusion is associated with chronic myeloid leukemia. CSK and Lck dysregulation are involved in autoimmune diseases through their roles in immune signaling pathways underlining their connection in pathological conditions.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
1 product image
Chemical Structure - 1-Naphthyl PP1, PKD inhibitor (ab145064)
2D chemical structure image of ab145064, 1-Naphthyl PP1, PKD inhibitor
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com